PHYSIOMICS PLC — Proxy Solicitation & Information Statement 2026

Apr 22, 2026

National Storage Mechanism | Additional information

RNS Number : 3905B

Physiomics PLC

22 April 2026

22 April 2026

Physiomics plc

("Physiomics" or the "Company")

Launch of Website for Requisitioned Meeting

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces the launch of a dedicated website aimed at providing key information to shareholders considering their vote in relation to the Company's forthcoming Requisitioned General Meeting to be held at 10.00 a.m. on 29 April 2026 ("Requisitioned General Meeting").

The website is available at www.pycrequisition.co.uk and has been created to ensure that all shareholders have access to transparent, accurate, and relevant information as they prepare for the upcoming shareholder vote. The site includes:

·    Circular containing information on the requisition;

·    Board's position regarding the requisition;

·    Board's recommendations to shareholders; and

·    Details of how to vote and key deadlines.

Physiomics is committed to maintaining open and constructive engagement with its shareholders and the launch of this dedicated website forms part of the Company's broader efforts to ensure shareholders can make informed decisions.

For more information about Physiomics and its services, please visit www.physiomics.co.uk

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.   

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCZZGZDMMNGVZZ